Activators of cxcr3 for the treatment of angiopathies of the eye
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsAlan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
Life of this patent
Estimating the term…
Abstract
The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof.
Claims25
A method of treating an angiogenic disorder of the eye, or treating or inhibiting aberrant angiogenesis of the eye, comprising selecting a subject with an angiogenic disorder of the eye or with aberrant angiogenesis of the eye, and administering to the subject a therapeutically effective amount of an activator of CXCR3, thereby treating the angiogenic disorder, or treating or inhibiting the aberrant angiogenesis.
(canceled)
24-27. (canceled)
Dependencies are inferred from the claim text.